Short Interest in Liminatus Pharma Inc. (NASDAQ:LIMN) Decreases By 99.1%

Liminatus Pharma Inc. (NASDAQ:LIMN) was the recipient of a significant decrease in short interest during the month of August. As of August 31st, there was short interest totaling 95,505 shares, a decrease of 99.1% from the August 15th total of 10,331,073 shares. Currently, 8.8% of the company’s stock are short sold. Based on an average daily volume of 71,248 shares, the days-to-cover ratio is presently 1.3 days.

Liminatus Pharma Trading Up 4.3%

Shares of LIMN traded up $0.15 during trading hours on Thursday, reaching $3.63. 19,007 shares of the stock traded hands, compared to its average volume of 619,206. Liminatus Pharma has a 52 week low of $3.42 and a 52 week high of $141.50. The company has a market cap of $4.86 million, a price-to-earnings ratio of -0.15 and a beta of 5.30. The stock has a fifty day simple moving average of $5.35 and a 200 day simple moving average of $7.89.

Liminatus Pharma (NASDAQ:LIMN) last issued its quarterly earnings data on Friday, August 14th. The company reported ($1.50) earnings per share (EPS) for the quarter.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the company. Wall Street Zen cut Liminatus Pharma to a “strong sell” rating in a research report on Saturday, August 22nd. Weiss Ratings lowered Liminatus Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, September 3rd. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company has an average rating of “Sell”.

About Liminatus Pharma

Liminatus Pharma, Inc is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.